See more : Yancoal Australia Ltd (YACAF) Income Statement Analysis – Financial Results
Complete financial analysis of Personalis, Inc. (PSNL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Personalis, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ) Income Statement Analysis – Financial Results
- C.H. Robinson Worldwide, Inc. (CHRW) Income Statement Analysis – Financial Results
- Acter Group Corporation Limited (5536.TWO) Income Statement Analysis – Financial Results
- Patagonia Lithium Limited (PL3.AX) Income Statement Analysis – Financial Results
- Shenzhen Forms Syntron Information Co., Ltd. (300468.SZ) Income Statement Analysis – Financial Results
Personalis, Inc. (PSNL)
About Personalis, Inc.
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 73.48M | 65.05M | 85.49M | 78.65M | 65.21M | 37.77M | 9.39M |
| Cost of Revenue | 55.27M | 51.70M | 53.84M | 58.53M | 43.13M | 25.97M | 11.74M |
| Gross Profit | 18.21M | 13.35M | 31.66M | 20.11M | 22.08M | 11.81M | -2.34M |
| Gross Profit Ratio | 24.78% | 20.52% | 37.03% | 25.57% | 33.86% | 31.25% | -24.94% |
| Research & Development | 64.78M | 64.91M | 49.31M | 28.57M | 22.42M | 14.30M | 9.92M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.27M | 9.90M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.73M | 63.97M | 47.70M | 33.69M | 22.08M | 11.27M | 9.90M |
| Other Expenses | 13.64M | 61.00K | -42.00K | -24.00K | -1.44M | -33.00K | -227.00K |
| Operating Expenses | 128.14M | 128.88M | 97.01M | 62.26M | 44.50M | 25.58M | 19.82M |
| Cost & Expenses | 183.42M | 180.58M | 150.85M | 120.79M | 87.63M | 51.54M | 31.56M |
| Interest Income | 5.90M | 2.40M | 367.00K | 949.00K | 1.62M | 293.00K | 100.00K |
| Interest Expense | 110.00K | 201.00K | 184.00K | 2.00K | 1.13M | 1.89M | 1.30M |
| Depreciation & Amortization | 11.30M | 12.88M | 8.96M | 7.17M | 5.73M | 3.07M | 1.22M |
| EBITDA | -96.81M | -104.64M | -59.01M | -34.05M | -18.21M | -14.92M | -21.07M |
| EBITDA Ratio | -131.74% | -173.83% | -76.06% | -45.09% | -34.10% | -27.65% | -224.36% |
| Operating Income | -109.94M | -115.53M | -65.35M | -42.15M | -22.42M | -13.77M | -22.16M |
| Operating Income Ratio | -149.61% | -177.61% | -76.44% | -53.59% | -34.38% | -36.45% | -235.95% |
| Total Other Income/Expenses | 1.72M | 2.26M | 141.00K | 923.00K | -2.66M | -6.11M | -1.43M |
| Income Before Tax | -108.21M | -113.28M | -65.21M | -41.22M | -25.08M | -19.88M | -23.59M |
| Income Before Tax Ratio | -147.27% | -174.14% | -76.28% | -52.41% | -38.45% | -52.63% | -251.18% |
| Income Tax Expense | 83.00K | 40.00K | 14.00K | 57.00K | 9.00K | 7.00K | 5.00K |
| Net Income | -108.30M | -113.32M | -65.23M | -41.28M | -25.08M | -19.89M | -23.60M |
| Net Income Ratio | -147.38% | -174.20% | -76.29% | -52.49% | -38.47% | -52.64% | -251.23% |
| EPS | -2.25 | -2.48 | -1.49 | -1.06 | -0.80 | -0.91 | -1.08 |
| EPS Diluted | -2.25 | -2.48 | -1.49 | -1.06 | -0.80 | -0.91 | -1.08 |
| Weighted Avg Shares Out | 48.18M | 45.70M | 43.89M | 39.11M | 31.24M | 21.75M | 21.75M |
| Weighted Avg Shares Out (Dil) | 48.18M | 45.70M | 43.89M | 39.11M | 31.24M | 21.75M | 21.75M |
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript
Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
Personalis to Participate at Upcoming Investor Conferences
Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
Source: https://incomestatements.info
Category: Stock Reports